small molecule

EXKIVITY

MOBOCERTINIB SUCCINATE

Loss of exclusivityMay 2035latest FDA-listed patent expiry

CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand name	EXKIVITY
Active ingredient	MOBOCERTINIB SUCCINATE
Strength	EQ 40MG BASE
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	September 2021
Marketing status	DISCN

Listed patents

Patent	Expires	Type
10227342	May 2035	substance, product
9796712	May 2035	substance, product

Regulatory exclusivity

Code	Expires
ODE-374	September 2028
NCE	September 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from TAKEDA PHARMACEUTICALS USA INC